These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38133462)

  • 1. Stakeholder Perspectives of the Inflation Reduction Act's (2022) Impact on Prescription Drugs: A Narrative Review.
    Lieneck C; McLauchlan M; Adachi V; Billings R
    Pharmacy (Basel); 2023 Dec; 11(6):. PubMed ID: 38133462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Inflation Reduction Act: How Will Medicare Negotiating Drug Prices Impact Patients with Heart Disease?
    Johnson M; Kishore S; Nayak RK; Dusetzina SB
    Curr Cardiol Rep; 2023 Jun; 25(6):577-581. PubMed ID: 37097432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How The ACA Reframed The Prescription Drug Market And Set The Stage For Current Reform Efforts.
    Conti R; Dusetzina SB; Sachs R
    Health Aff (Millwood); 2020 Mar; 39(3):445-452. PubMed ID: 32119622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examining Opportunities to Increase Savings From Medicare Price Negotiations.
    Reitsma MB; Dusetzina SB; Ballreich JM; Trujillo AJ; Mello MM
    JAMA Intern Med; 2023 Jun; 183(6):581-588. PubMed ID: 37067794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should the United States government regulate prescription prices? A critical review.
    Patterson JA; Carroll NV
    Res Social Adm Pharm; 2020 May; 16(5):717-723. PubMed ID: 31248779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
    Raimond VC; Feldman WB; Rome BN; Kesselheim AS
    Milbank Q; 2021 Mar; 99(1):240-272. PubMed ID: 33751664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "What's up with price controls?" Stakeholders' views on the regulation of pharmaceutical pricing in Malaysia.
    Loh YSL; Siah AKL; Koh SGM; Cheong WL; Su TT
    PLoS One; 2023; 18(12):e0291031. PubMed ID: 38060579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do market components account for higher US prescription prices?
    Monaghan MJ; Monaghan MS
    Ann Pharmacother; 1996 Dec; 30(12):1489-94. PubMed ID: 8968463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Risk Factors Under the Inflation Reduction Act.
    Narasimmaraj PR; Oseran A; Tale A; Xu J; Essien UR; Kazi DS; Yeh RW; Wadhera RK
    J Am Coll Cardiol; 2023 Apr; 81(15):1491-1501. PubMed ID: 37045519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the Impact of the Inflation Reduction Act on the Out-of-Pocket Costs for Medicare Beneficiaries With Advanced Prostate Cancer.
    Cortese BD; Dusetzina SB; Al Hussein Al Awamlh B; Penson DF; Chang SS; Barocas DA; Luckenbaugh AN; Scarpato KR; Moses KA; Talwar R
    Urol Pract; 2023 Sep; 10(5):476-483. PubMed ID: 37409930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMCP Guide to Pharmaceutical Payment Methods.
    AMCP Task Force on Drug Payment Methodologies
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl C):S1-39. PubMed ID: 17970611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
    Mendoza RL
    J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using a patient-centered value assessment to optimize fair prices for Inflation Reduction Act's Medicare Drug Price Negotiation Program.
    Poudel N; Ngorsuraches S
    J Manag Care Spec Pharm; 2024 Mar; 30(3):241-246. PubMed ID: 38140902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value added medicines: what value repurposed medicines might bring to society?
    Toumi M; Rémuzat C
    J Mark Access Health Policy; 2017; 5(1):1264717. PubMed ID: 28265347
    [No Abstract]   [Full Text] [Related]  

  • 15. Challenges to pharmaceutical policymaking: lessons from Australia's national medicines policy.
    Lipworth W; Doran E; Kerridge I; Day R
    Aust Health Rev; 2014 May; 38(2):160-8. PubMed ID: 24589424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022.
    Rome BN; Nagar S; Egilman AC; Wang J; Feldman WB; Kesselheim AS
    JAMA Health Forum; 2023 Jan; 4(1):e225218. PubMed ID: 36705916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Financial aspects and the future of the pharmaceutical industry in the United States of america.
    Karamehic J; Ridic O; Ridic G; Jukic T; Coric J; Subasic D; Panjeta M; Saban A; Zunic L; Masic I
    Mater Sociomed; 2013 Dec; 25(4):286-90. PubMed ID: 24511277
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.